{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:02:25Z","timestamp":1747152145482,"version":"3.40.5"},"reference-count":37,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[2022,8,15]]},"abstract":"<jats:p>Mucopolysaccaridosis IIIA (MPS IIIA) is a rare genetic disease that afflicts children and leads to neurocognitive degeneration. We develop a Bayesian disease progression model (DPM) of MPS IIIA that characterizes the pattern of cognitive growth and decline in this disease. The DPM is a repeated measures model that incorporates a nonlinear developmental trajectory and shape\u2010invariant random effects. This approach quantifies the pattern of cognitive development in MPS IIIA and addresses differences in biological age, length of follow\u2010up, and clinical outcomes across natural history subjects. The DPM can be used in clinical trials to estimate the percent slowing in disease progression for treatment relative to natural history. Simulations demonstrate that the DPM provides substantial improvements in power relative to alternative analyses.<\/jats:p>","DOI":"10.1002\/sim.9435","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T06:52:39Z","timestamp":1652511159000},"page":"3579-3595","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian model of disease progression in mucopolysaccaridosis IIIA"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-5194","authenticated-orcid":false,"given":"Joe","family":"Marion","sequence":"first","affiliation":[{"name":"Berry Consultants  Austin Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Forge Biologics  Grove City Ohio USA"},{"name":"Abeona Therapeutics  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-7171","authenticated-orcid":false,"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[{"name":"Berry Consultants  Austin Texas USA"},{"name":"Department of Biostatistics Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S57672"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-43"},{"key":"e_1_2_13_4_1","unstructured":"Food and Drug Administration U.S. Department of Health and Human Services.Innovation or stagnation? Challenge and opportunity on the critical path to new medical products; 2004."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.07.005"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26644"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8050"},{"key":"e_1_2_13_8_1","first-page":"115","article-title":"A Bayesian approach to multi\u2010state hidden Markov models: application to dementia progression","author":"Williams J","year":"2018","journal-title":"J Am Stat Assoc"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1198\/016214504000001592"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780130803"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/2986089"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9661-8"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.08.002"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.11.079"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.12.396"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0675-4"},{"key":"e_1_2_13_17_1","unstructured":"U. S. Food and Drug Administration.Center for drug evaluation and research. center for biologics evaluation and research. mucopolysaccharidosis type III (Sanfilippo Syndrome): developing drugs for treatment guidance for industry; 2020."},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.05.004"},{"volume-title":"Mullen Scales of Early Learning Manual","year":"1995","author":"Mullen EM","key":"e_1_2_13_19_1"},{"volume-title":"Bayley Scales of Infant and Toddler Development","year":"2006","author":"Bayley N","key":"e_1_2_13_20_1"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-008-0838-5"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84858-7"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1972.10488942"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780141807"},{"issue":"5","key":"e_1_2_13_25_1","first-page":"S400","article-title":"Estimating long\u2010term multivariate progression from short\u2010term data","volume":"10","author":"Donohue MC","year":"2014","journal-title":"Alzheimers Dement"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq115"},{"volume-title":"Bayesian Data Analysis","year":"2004","author":"Gelman A","key":"e_1_2_13_27_1"},{"key":"e_1_2_13_28_1","unstructured":"PlummerM.JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling; 2003."},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.03.002"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","unstructured":"KimA PoeM EscolarML.Mullen scales of early learning and bayley scales of infant and toddler development and its utility in assessing cognitive endpoints in clinical trials for patients with mucopolysaccharidoses. Paper presented at: Proceedings of the World Symposium; February 8\u2010February 12 2021.","DOI":"10.1016\/j.ymgme.2020.12.122"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608075"},{"key":"e_1_2_13_32_1","unstructured":"U. S. Food and Drug Administration Office of the Commissioner Office of Clinical Policy and Programs Office of Orphan Products Development. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research.Rare diseases: natural history studies for drug development draft guidance for industry; 2019."},{"key":"e_1_2_13_33_1","unstructured":"Proceedings of the International Conference on Harmonisation E10. Choice of Control Group in Clinical Trials; 2001."},{"issue":"1","key":"e_1_2_13_34_1","first-page":"181","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"Lee JH","year":"2020","journal-title":"Mol Genet Metab"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2014.888569"},{"key":"e_1_2_13_36_1","article-title":"Observational prospective natural history of patients with sanfilippo syndrome type B","volume":"197","author":"Whiteley CB","year":"2018","journal-title":"J Pediatr"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19394"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.9435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sim.9435","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.9435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:50:30Z","timestamp":1692255030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.9435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":37,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,8,15]]}},"alternative-id":["10.1002\/sim.9435"],"URL":"https:\/\/doi.org\/10.1002\/sim.9435","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"type":"print","value":"0277-6715"},{"type":"electronic","value":"1097-0258"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"2021-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}